ThromboGenics reported an increase in cash and investments in the third quarter of 2017 compared with the second quarter of the year, according to a company press release.
Cash and investments totaled 113.4 million euros at the end of September compared with 65.1 million euros at the end of June.
The company recently regained its non-U.S. rights to Jetrea (ocriplasmin) from Alcon and now owns the global rights to the treatment for vitreomacular adhesion and vitreomacular traction.
“The 53 million euros cash payment that we received as part of our (Read more...)
Uncategorized